Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases
| Autor: | Nicola Fabbri, Cristiana Forni, Mario Mercuri, Piero Picci, Gaetano Bacci, Enza Barbieri, Alba Balladelli, Antonio Briccoli, Alessandra Longhi, Stefano Ferrari |
|---|---|
| Přispěvatelé: | G. Bacci, A. Longhi, C. Forni, N. Fabbri, A. Briccoli, E. Barbieri, M. Mercuri, A. Balladelli, S. Ferrari, P. Picci |
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Neoplasms Radiation-Induced Adolescent medicine.medical_treatment Bone Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Ifosfamide Child Retrospective Studies Osteosarcoma Acute leukemia Chemotherapy Radiation business.industry medicine.disease Primary tumor Neoadjuvant Therapy Conventional Osteosarcoma Surgery Leukemia Methotrexate Oncology Chemotherapy Adjuvant Child Preschool Female Cisplatin business Follow-Up Studies medicine.drug |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 67:505-511 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/j.ijrobp.2006.08.072 |
| Popis: | Purpose: Evaluate treatment and outcome of 20 patients with radioinduced osteosarcoma (RIO). Because of previous primary tumor treatment, RIO protocols were different from others we used for non-RIO. Patients and Methods: Between 1983 and 1998, we treated 20 RIO patients, ages 4–36 years (mean 16 years), with chemotherapy (two cycles before surgery, three postoperatively). The first preoperative cycle consisted of high-dose Methotrexate (HDMTX)/Cisplatinum (CDP)/Adriamycin (ADM) and the second of HDMTX/CDP/Ifosfamide (IFO). The three postoperative treatments were performed with cycles of MTX/CDP; IFO was used as single agent per cycle repeated three times. Results: Two patients received palliative treatment because their osteosarcoma remained unresectable after preoperative chemotherapy. The remaining 18 patients had surgery (7 amputations, 11 resections); histologic response to preoperative chemotherapy was good in 8 patients, poor in 10. At a mean follow-up of 11 years (range, 7–22 years), 9 patients remained continuously disease-free, 10 died from osteosarcoma and 1 died from a third neoplasm (myeloid acute leukemia). These results are not significantly different from those achieved in 754 patients with conventional osteosarcoma treated in the same period with protocols used for conventional treatment. However, this later group had an 18% 3-year event-free survival after treatment of relapse vs. 0% in the RIO group. Conclusion: Treated with neoadjuvant chemotherapy RIO seem to have an outcome that is not significantly different from that of comparable patients with conventional primary high grade osteosarcoma (5-year event-free survival: 40% vs. 60%, p = NS; 5-year overall survival 40% vs. 67%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|